menu
    • menu

    Company profile for PeptiDream

    NEW Drugs in Dev: 1
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    LEBSA- Your strategic API source for niche molecules.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    PeptiDream Inc. is a public (Tokyo Stock Exchange 1st Section 4587) biopharmaceutical company founded in 2006 employing our proprietary Peptide Discovery Platform System(PDPS), a state-of-the-art highly versatile discovery platform which enables the production of highly diverse (trillions) non-standard peptide libraries with high efficiency, for the identification of highly potent and selective hit candidates, which then can b...
    PeptiDream Inc. is a public (Tokyo Stock Exchange 1st Section 4587) biopharmaceutical company founded in 2006 employing our proprietary Peptide Discovery Platform System(PDPS), a state-of-the-art highly versatile discovery platform which enables the production of highly diverse (trillions) non-standard peptide libraries with high efficiency, for the identification of highly potent and selective hit candidates, which then can be developed into peptide-based, small molecule-based, or peptide-drug-conjugate-based therapeutics. PeptiDream aspires to be a world leader in drug discovery and development to address unmet medical need.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    PeptiDreamjapan Flag
    Country
    Country
    Japan
    Address
    Address
    210-0821 3-25-23 Tonomachi, Kawasaki-ku, Kawasaki City, Kanagawa Prefecture
    Telephone
    Telephone
    +81-44-270-1300
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.peptidream.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/peptidream-inc-4587-/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/peptidream

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    PeptiDream, Alnylam Reach Milestone In Targeted Sirna Delivery
    PeptiDream, Alnylam Reach Milestone In Targeted Sirna Delivery

    18 Dec 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251218982036/en/PeptiDream-and-Alnylam-Announce-Achievement-of-Key-Milestone-in-siRNA-Conjugate-Discovery-Collaboration-Demonstrating-Peptide-Ligand-Mediated-Targeted-siRNA-Delivery-to-Specific-Extrahepatic-Tissues

    BUSINESSWIRE
    18 Dec 2025
    Share Share
    PeptiDream Announces Oral Dual IL-17A/F Inhibitor Results
    PeptiDream Announces Oral Dual IL-17A/F Inhibitor Results

    17 Dec 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251217522525/en/PeptiDream-Announces-Promising-Pre-Clinical-Results-of-Proprietary-Oral-IL-17A-and-IL-17F-Dual-Inhibitor-with-Biologic-Like-Efficacy-for-the-Treatment-of-Psoriasis

    BUSINESSWIRE
    17 Dec 2025
    Share Share
    Curium, PeptiDream Start 64Cu-PSMA-I&T Prostate Cancer Trial
    Curium, PeptiDream Start 64Cu-PSMA-I&T Prostate Cancer Trial

    15 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/15/3166805/0/en/Curium-Group-PeptiDream-and-PDRadiopharma-Enroll-First-Patient-to-Registrational-Clinical-Trial-of-64Cu-PSMA-I-T-for-Prostate-Cancer-in-Japan.html

    GLOBENEWSWIRE
    15 Oct 2025
    Share Share
    Japan's National Cancer Center & PeptiDream Develop New Radiopharma
    Japan's National Cancer Center & PeptiDream Develop New Radiopharma

    28 Mar 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250328335990/en/National-Cancer-Center-Japan-and-PeptiDream-New-Radiopharmaceuticals-for-Renal-Cell-Carcinoma

    BUSINESSWIRE
    28 Mar 2025
    Share Share
    PeptiDream Shows Oral Myostatin Inhibitors Prevent Lean Mass Loss
    PeptiDream Shows Oral Myostatin Inhibitors Prevent Lean Mass Loss

    12 Dec 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241212633930/en

    BUSINESSWIRE
    12 Dec 2024
    Share Share
    PeptiDream Advances Peptide Therapy for Gastric Cancer Claudin 18.2
    PeptiDream Advances Peptide Therapy for Gastric Cancer Claudin 18.2

    12 Dec 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241212512779/en

    BUSINESSWIRE
    12 Dec 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search